CoChat
Sign Up
Cited by 126Rheumatoid Arthritis Research and TherapiesHealth Systems, Economic Evaluations, Quality of LifeBiosimilars and Bioanalytical Methods

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation

Open access
Jobanputra, P., Barton, P., Bryan, S., Burls, A.·2002·Health Technology Assessment
DOI 10.3310/hta6210
Open this paper in CoChat — free accountOpen PDF

Abstract

CostsAn incremental economic analysis was undertaken to estimate the additional costs and quality-adjusted life-year (QALY) gains associated with the use of either etanercept or infliximab, either as the third DMARD in a sequence of DMARDs or separately as last-resort therapy (i.e.used last in a DMARD sequence).A simulation model was constructed that considered improvements in quality of life but assumed no effect of either etanercept or infliximab on mortality or the need for joint replacement.For use as the third DMARD in a sequence of DMARDs, the Birmingham Preliminary Model gave a base-case incremental cost-effectiveness ratio of approximately £83,000 per QALY for etanercept and approximately £115,000 per QALY for infliximab.These figures reduced to £72,000 per QALY for etanercept, and £95,000 for infliximab, if they were used last in the sequence of DMARDs.Sensitivity analysis in the latter case gave figures ranging from £47,000 to £128,000 for etanercept and £62,000 to £169,000 for infliximab.It should be stressed that these figures do not include all benefits.Further research is needed on the effect of all DMARDs on joint replacement, hospitalisation, mortality and quality of life.the American Rheumatism Association (ARA) in 1987, are shown in Table 1.6 These criteria were derived from a group of typical patients who had been diagnosed with RA and had well-established

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3310/hta6210

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Neutralizing antibodies against key SASP components or their receptors, including IL-6, IL-1α, IL-1β, and TNF, have demonstrated senomorphic effects.

    “A number of neutralizing antibodies directed against key components of the SASP or their receptors, including IL-6, IL-1α, IL-1β and TNF, also have shown senomorphic properties104,240–248 (TABLE 1).”

    From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [246]

    The References section identifies infliximab as an anti-TNFα monoclonal antibody, and the Role of TNF section discusses effects of anti-TNF therapy in rheumatoid arthritis. Our copy does not report senomorphic effects or establish that antibodies against IL-6, IL-1α, or IL-1β have such effects. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 139 references couldn’t be matched to a known paper.

Research works printed but not linked: 33

  1. [2]2. Wolfe F, Zwillich S. The long-term outcome of rheumatoid arthritis. A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1072-82.
  2. [7]7. Harrison B, Symmons D, Barrett E, Silman A. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 1998;25:2324-30.
  3. [8]8. Wiles N, Symmons D, Harrison B, Barrett E, Barrett J, Scott D, et al. Estimating the incidence of rheumatoid arthritis. Trying to hit a moving target? Arthritis Rheum 1999;42:1339-46.
  4. [11]11. MacGregor A, Snieder H, Rigby A, Koskenvuo M, Kapiro J, Aho K. Characterising the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-7.
  5. [12]12. Barton A, John S, Ollier W, Silman A, Worthington J. Association between rheumatoid arthritis and polymorphisms of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I in Caucasians. Arthritis Rheum 2001;44:61-5.
  6. [20]20. Brennan F, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
  7. [23]23. Beutler B, Cerami A. The biology of cachetin/ TNF -a primary mediator of the host response. Annu Rev Immunol 1989;7:625-55.
  8. [28]28. Taylor P, Peters A, Paleolog E, Chapman P, Elliott M, McCloskey R, et al. Reduction of chemo- kine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38-47.
  9. [38]38. Hickling P, Jacoby R, Kirwan J, The Arthritis Rheumatism Council Low-Dose Corticosteroid Study Group. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998;37:930-6.
  10. [43]43. Jeurissen M, Boerbooms A, van de Putte A, Doesburg W, Mulder J, Rasker J. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight week randomised double- blind study. Arthritis Rheum 1991;34:961-72.
  11. [49]49. Proudman S, Conaghan P, Richardson C, Griffiths B, Green M, McGonagle D, et al. Treatment of poor prognosis early rheumatoid arthritis. A randomised study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulphasalazine alone. Arthritis Rheum 2000;43:1809-19.
  12. [55]55. Pincus T, Marcum S, Callahan L. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisolone. J Rheumatol 1992;19:1885-94.
  13. [57]57. Gøtzche P, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang K. Randomised placebo con- trolled trial of withdrawal of slow-acting drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 1996;25:194-9.
  14. [60]60. Denman A. Antirheumatic drugs. In: Maddison P, Isenberg D, Woo P, Glass D, editors. Oxford textbook of rheumatology. Oxford: Oxford University Press; 1998. p. 581-608.
  15. [62]62. Felson D, Anderson J, Lange M, Wells G, LaValley M. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
  16. [71]71. Vliet Vlieland T, Breedveld F, Hazes J. The two-year follow-up of a randomised comparison of inpatient multidisciplinary team care and routine outpatient care for active rheumatoid arthritis. Br J Rheumatol 1997;36:82-5.
  17. [74]74. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, et al. How does disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years follow-up in 732 patients from the early RA Study (ERAS). Rheumatology 2000;39:603-11.
  18. [80]80. Valenzuela-Castano A, Garcia-Lopez A, Perez- Vilches D, Rodriguez-Perez R, Gonzalez- Escribano M, Nunez-Roldan A. The predictive value of the HLA shared epitope for severity of radiological joint damage in patients with rheumatoid arthritis. A 10 year observational study. J Rheumatol 2000;27:571-4.
  19. [132]132. Moreland L, Schiff M, Baumgartner S, Tindall E, Fleischmann R, Bulpitt K. Etanercept therapy in rheumatoid arthritis: a randomised, controlled trial. Ann Intern Med 1999;130:478-86.
  20. [137]137. Ericson M, Wajdula J, on behalf of the European Etanercept Investigators Group. A double-blind, placebo controlled study of the efficacy and safety of four different doses of etanercept in patients with rheumatoid arthritis. Arthritis Rheum 1999;42:S82.
  21. [143]143. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralisation in MS -results of a randomised, placebo-controlled multicentre study. Neurology 1999;53:457-65.
  22. [151]151. Yelin E, Wanke L. An assessment of the annual and long-term direct costs of rheumatoid arthritis. Arthritis Rheum 1999;42:1209-18.
  23. [156]156. Choi H, Seeger J, Kuntz K. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316-27.
  24. [159]159. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
  25. [170]170. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
  26. [171]171. Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis (Cochrane Review). In: The Cochrane Library. Issue 2. Oxford: Update Software; 2000.
  27. [174]174. van Gestel A, Prevoo M, Van't Hof M, Rijswijk M, van Riel P. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1995;39:34-40.
  28. [175]175. van Gestel A, Haagsma C, van Riel P. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
  29. [184]184. Buch M, Jarrett S, Bingham S, Marzo-Ortega H, Fairclough A, Emery P. Incidence of adverse events in patients with rheumatoid arthritis receiving infliximab. Rheumatology 2001;40:32-3.
  30. [186]186. Conaghan P, Quinn M, O'Connor P, Wakefield R, Karim Z, Astin P, et al. Can high-dose infliximab achieve remission in early rheumatoid arthritis. Rheumatology 2001;40:31-2.
  31. [187]187. Cope A, Maini R. Soluble tumor necrosis factor receptor in arthritis. J Rheumatol 1995;22:382-4.
  32. [189]189. Crnkic M, Teleman A, Saxne T, Geborek P. Infliximab, etanercept and leflunomide in rheumatoid arthritis. Clinical experience in southern Sweden. Rheumatology 2001;40:82. 190.
  33. [232]232. Ostrov B. Beneficial effect of etanercept on rheu- matoid lymphedema. Arthritis Rheum 2001;44:240-1.

Cited by

Sorted by citations

Related

Authors
Jobanputra, P., Barton, P., Bryan, S., & Burls, A.
Affiliations
  • Selly Oak Hospital (GB)
  • University of Birmingham (GB)
ORCID
Venue
Health Technology Assessment
Publisher
National Institute for Health and Care Research
Published
2002
Volume
6
Issue
21
Pages
1-110
ISSN
  • 1366-5278 (ISSN-L)
  • 2046-4924
DOI
10.3310/hta6210
OpenAlex
W2097585904
Cited by
126
References
139
Citations by year
2022: 1 · 2021: 1 · 2020: 5 · 2018: 1 · 2017: 4 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 4 · 2012: 5
FWCI
1.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Health Technology Assessment (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Funders
Health Technology Assessment programme (00/18/01)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords
rheumatoid arthritis, infliximab, etanercept, TNF-alpha inhibitors, cost-effectiveness, quality-adjusted life years, treatment costs
MeSH terms
Etanercept, Infliximab, Antibodies, Monoclonal, Arthritis, Rheumatoid, Cost-Benefit Analysis, Data Collection, Humans, Immunoglobulin G, United States, Placebo Effect, Randomized Controlled Trials as Topic, Treatment Outcome, Receptors, Tumor Necrosis Factor, Antirheumatic Agents, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review